Difference between revisions of "ANLY482 AY2017-18T2 Group32 : Project Findings"
| Line 57: | Line 57: | ||
However, as the TCE brands are at their end-of-life cycle, the accounts for these TCE brands are handled from the Sales Representatives to the Account Representatives (AR). The AR only need to call the doctors and nurses in each organization and try to sell a new product or convince them to buy another batch of an existing drug in their inventory. Hence, we are only focusing on the AR from the calls observation, to have a better understanding of their performance. | However, as the TCE brands are at their end-of-life cycle, the accounts for these TCE brands are handled from the Sales Representatives to the Account Representatives (AR). The AR only need to call the doctors and nurses in each organization and try to sell a new product or convince them to buy another batch of an existing drug in their inventory. Hence, we are only focusing on the AR from the calls observation, to have a better understanding of their performance. | ||
| − | ==<div style="background: #404040; padding: 15px; font-weight: bold; line-height: 0.3em; text-indent: 15px; font-size: 16px"><font color=#ffffff >2.0 | + | ==<div style="background: #404040; padding: 15px; font-weight: bold; line-height: 0.3em; text-indent: 15px; font-size: 16px"><font color=#ffffff >2.0 Initial Visualization Dashboard </font></div>== |
| Line 73: | Line 73: | ||
- | - | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
<b>4.1.1 - </b> <br> | <b>4.1.1 - </b> <br> | ||
Revision as of 23:04, 16 April 2018
| Interim | Final |
Contents
1.0 Initial Data Observation
We conducted an initial data observation to seek some initial insights between sales and healthcare organizations as well as to understand what products Pharma G's account representatives are pushing to healthcare practitioners.
For Invoice Data, after filtering for the TCE brands, here is a distribution of all the TCE brands and its sales performance.
Sales across various Channels
Pharma G appears to have a strong performance in 2016 but sales amount decreased by 9% to a 3-year low in 2017. This signals a need to for Pharma G to keep their sales team in check using Key Performance Indicators as mentioned above.
This could be attributed to the drop in sales from the general hospitals which generate 42% of yearly revenue. Pharma G saw a decrease in sales revenue from its top 3 buyers from 2016.
Lastly, the top three products brought in lesser revenue last year as compared to 2016. Most notably, their best selling drug saw a sharp decrease in sales last year, falling by 8.8%.
Telesales by Account Representative
89.6% of all interactions are face to face, which explains why interaction duration can go as high as >300 minutes as Sales Representatives may need more time to build rapport. In addition, there seems to be a correlation between the number of products pushed to the practitioner and the interaction duration. For a huge client like hospital, the representative may need to push for several product lines whereas a small clinic will only need a fraction of it.
However, as the TCE brands are at their end-of-life cycle, the accounts for these TCE brands are handled from the Sales Representatives to the Account Representatives (AR). The AR only need to call the doctors and nurses in each organization and try to sell a new product or convince them to buy another batch of an existing drug in their inventory. Hence, we are only focusing on the AR from the calls observation, to have a better understanding of their performance.
2.0 Initial Visualization Dashboard
2.1 Revised Metadata
-
3.0 Data
3.1 -
-
4.1.1 -
5.0 Exploratory Data Analysis and Interim Findings
6.1 New Data Sets
6.3 Revised Scope of Work
-
